Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with CancerIlaria Grazia Zizzari, Chiara Napoletano, Ernesto Rossi et al.|Clinical Cancer Research|2022Cited by 30
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137+T-cellsAlessio Ugolini, Marianna Nuti, Ilaria Grazia Zizzari et al.|EBioMedicine|2020Cited by 17
4P IgM-rheumatoid factor as a novel biomarker for a reduced survival in anti-PD-1 treated NSCLC patients through the decrease of CD137+ T-cellsAlessio Ugolini, Marianna Nuti, Ilaria Grazia Zizzari et al.|Annals of Oncology|2020Cited by 2
Supplementary Figure from Circulating CD137<sup>+</sup> T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with CancerIlaria Grazia Zizzari, Chiara Napoletano, Aurelia Rughetti et al.|Unknown|2023Cited by 0
Supplementary Figure from Circulating CD137<sup>+</sup> T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with CancerIlaria Grazia Zizzari, Chiara Napoletano, Alessandra Di Filippo et al.|Unknown|2023Cited by 0